ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 112 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,123,811 | -28.2% | 164,060 | +8.6% | 0.00% | -100.0% |
| Q2 2023 | $1,566,233 | +9.1% | 151,035 | -14.9% | 0.00% | 0.0% |
| Q1 2023 | $1,435,660 | +583.6% | 177,461 | +1354.6% | 0.00% | – |
| Q1 2022 | $210,000 | -69.8% | 12,200 | -74.5% | 0.00% | – |
| Q4 2021 | $695,000 | -28.9% | 47,828 | -12.0% | 0.00% | – |
| Q3 2021 | $978,000 | +29.4% | 54,320 | +26.3% | 0.00% | – |
| Q2 2021 | $756,000 | -28.2% | 43,000 | +2.9% | 0.00% | – |
| Q1 2021 | $1,053,000 | +1184.1% | 41,802 | +229.1% | 0.00% | – |
| Q4 2020 | $82,000 | +7.9% | 12,701 | -56.9% | 0.00% | – |
| Q3 2020 | $76,000 | -76.8% | 29,472 | -85.4% | 0.00% | – |
| Q2 2020 | $328,000 | +1950.0% | 202,183 | +1296.7% | 0.00% | – |
| Q3 2019 | $16,000 | -76.8% | 14,476 | -54.1% | 0.00% | – |
| Q2 2019 | $69,000 | – | 31,547 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |